INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of September 19, 2025 Lead Plaintiff Deadline in the Alto Neuroscience, Inc. (ANRO) Class Action – Investors With Significant Losses Encouraged to Contact the Firm

Core Points - A shareholder class action lawsuit has been filed against Alto Neuroscience, Inc. alleging that the company made materially false and misleading statements regarding its drug ALTO-100 and its effectiveness in treating Major Depressive Disorder (MDD) [1] - The lawsuit claims that the clinical, regulatory, and commercial prospects of ALTO-100 were overstated, leading to an inflated perception of Alto's business and financial prospects [1] Legal Context - Shareholders who purchased Alto shares between February 2, 2024, and October 22, 2024, and suffered significant losses are encouraged to discuss their legal rights [2] - The deadline to request appointment as lead plaintiff in the case is September 19, 2025 [3]